Bronchoalveolar lavage fluids (BALF) were analyzed for surfactant abnormalities in 153 patients with acute respiratory failure necessitating mechanical ventilation. Diagnoses were acute respiratory distress syndrome (ARDS) in the absence of lung infection (n = 16), severe pneumonia (PNEU; n = 88), ARDS and PNEU (n = 36), and cardiogenic lung edema (CLE; n = 13). The PNEU group was subdivided into groups with alveolar PNEU (n = 35), bronchial PNEU (n = 16), interstitial PNEU (n = 18) and nonclassified PNEU (n = 19). Comparison with healthy controls (n = 20) was undertaken. Total phospholipids (PL), proteins, PL classes (HPTLC) and surfactant apoproteins SP-A and SP-B (ELISA) were quantified in the original BALF. The 48,000 x g pellet from centrifugation of the BAL was used to assess the percentage of large surfactant aggregates (LSA) and the biophysical properties of the surfactant (pulsating bubble surfactometer). All groups with inflammatory lung injury (PNEU and/or ARDS) showed some decrease in the lavageable PL pool, a reduced LSA content in BALF, and a manifold increase in alveolar protein load. Marked changes in the PL profile were noted throughout the groups (a decrease in phosphatidylcholine (PC) and phosphatidylglycerol (PG) and an increase in phosphatidylinositol [PI] and sphingomyelin [SPH]). Concentrations of SP-A but not of SP-B in BALF were reduced. Minimum surface-tension values approached 0 mN/m in controls, and ranged from 10 to 25 mN/m in the absence of supernatant protein and from 20 to 35 mN/m in recombination with leaked protein in the groups with ARDS and/or PNEU. Abnormalities in alveolar PNEU surpassed those in bronchial PNEU, and interstitial PNEU presented a distinct pattern with extensive metabolic changes. All surfactant changes were absent in CLE except for a slight inhibition of surface activity by proteins. We conclude that pronounced surfactant abnormalities, comparable to those in ARDS in the absence of lung infection, occur in different entities of severe PNEU, but not in CLE.
[1]
A. Jobe,et al.
Surfactant subtypes. In vitro conversion, in vivo function, and effects of serum proteins.
,
1994,
American journal of respiratory and critical care medicine.
[2]
J. Whitsett,et al.
Decreased surfactant protein A in patients with bacterial pneumonia.
,
1993,
The American review of respiratory disease.
[3]
W. Seeger,et al.
Surfactant protein A (SP‐A) is decreased in acute parenchymal lung injury associated with polytrauma *
,
1992,
European journal of clinical investigation.
[4]
M. Hallman.
Lung surfactant in respiratory distress syndrome
,
1991,
Acta anaesthesiologica Scandinavica. Supplementum.
[5]
J. Whitsett,et al.
Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins.
,
1991,
Chemistry and physics of lipids.
[6]
W. Johanson,et al.
Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome.
,
1986,
The American review of respiratory disease.
[7]
W. Seeger,et al.
Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro.
,
1985,
Biochimica et biophysica acta.